Comprehensive analysis of PathAI's strengths and weaknesses based on real user feedback and expert evaluation.
AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.
6 major strengths make PathAI stand out in the automation & workflows category.
Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.
5 areas for improvement that potential users should consider.
PathAI has potential but comes with notable limitations. Consider trying the free tier or trial before committing, and compare closely with alternatives in the automation & workflows space.
If PathAI's limitations concern you, consider these alternatives in the automation & workflows category.
Clinical decision support AI that assists healthcare professionals with differential diagnosis, medical knowledge search, and evidence-based clinical reasoning.
AI-powered medical imaging platform that accelerates diagnosis and treatment of critical conditions
AI clinical insights platform that reviews 100% of patient charts to support hospital documentation, diagnosis capture, and revenue integrity workflows.
PathAI is used for AI-powered digital pathology workflows, including image management, case management, biomarker analysis, clinical trial histology assessment, tumor microenvironment analysis, and AI-assisted pathology research.
PathAI states that AISight Dx, its digital pathology image management system, is FDA-cleared for primary diagnosis in the United States. Many individual PathAI algorithms are listed as Research Use Only in the United States and not for diagnostic procedures.
PathAI is best suited for anatomic pathology laboratories, academic medical centers, reference laboratories, health systems, central labs, and biopharma companies working on biomarker discovery, clinical trials, or digital pathology transformation.
No public self-serve pricing is listed on the website. PathAI uses enterprise pricing based on deployment needs, platform scope, AI products, services, and clinical trial or laboratory requirements. Buyers need to request a quote from PathAI sales for exact contract pricing.
The website presents PathAI as AI-powered pathology technology intended to support pathology workflows, improve histology assessment, and assist research or clinical trial processes. It does not describe the platform as replacing pathologists.
Consider PathAI carefully or explore alternatives. The free tier is a good place to start.
Pros and cons analysis updated March 2026